NK CellTech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A developer of off-the-shelf allogeneic natural killer (NK) cell therapies for cancer.
OncologyCell Therapy
Technology Platform
A platform for manufacturing and engineering allogeneic natural killer (NK) cells to create off-the-shelf cellular immunotherapies.
Opportunities
The promise of an off-the-shelf, potentially safer cell therapy could revolutionize accessibility and cost in cancer treatment.
Risk Factors
Unproven clinical efficacy of CAR-NK cells compared to established CAR-T therapies, and challenges with in vivo persistence of NK cells.
Competitive Landscape
Part of a growing but unproven field of allogeneic NK cell therapy, competing to validate the platform's clinical and commercial potential.